WuXi XDC Continues to Deliver Robust Business Growth and Financial Results in 1H 2025, Strengthening Global CRDMO Leadership Position in Bioconjugates Industry

– Revenue increased by 62.2% YoY to RMB 2,701 million – Gross profit surged by 82.2% YoY to RMB 975 million, with its margin of 36.1% – Adjusted net profit before interest income and expense increased by 69.6% YoY to RMB 733 million, with its margin of 27.1% – Adjusted net profit…